SIRPA and neoplasm: In preclinical trials, mice bearing primary breast tumors exhibited significantly reduced tumor growth and lung metastasis as a result of this approach.1048 Moreover, hybrid nanovesicles (hEL-RS17), which are functionalized with the RS17 peptide—an antitumor agent that blocks CD47-SIRPα signaling—were shown to actively target tumor cells and modulate TAM phenotypes to enhance tumor infiltration.